Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 23 February 2012
Fourteen Chinese companies have been linked to contaminated heparin, an anticoagulant commonly used during surgical procedures and dialysis, according to a Wall Street Journal report.
The US Food and Drug Administration (FDA) added these companies to an import list allowing FDA to stop shipments at the border. That list already included eight other Chinese suppliers who were believe to have provided tainted raw materials for the making of heparin.
The Wall Street Journal reported the materials were delivered in 2008 and FDA doesn't have any evidence that the Chinese companies are currently supplying bad ingredients.
An estimated 12 million Americans use heparin each year, according to the report.
Read more:The Wall Street Journal: Suppliers Linked to Impure HeparinThe New York Times: F.D.A. Lists Sources of Tainted Drug
Tags: supplies, Heparin, Ban, Import, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.